公开(公告)号：US20170190775A1

公开(公告)日：2017-07-06

申请号：US15372600

申请日：2016-12-08

Applicant: Novo Nordisk A/S

Inventor： Vibeke Westphal STENNICKE ,  Christine Brender Read ,  Susanne Nedergaard Grell ,  Charlotte Wiberg ,  Rune SaIbo ,  Anette Henriksen ,  Soeren Padkjaer

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US20130211050A1

公开(公告)日：2013-08-15

申请号：US13690748

申请日：2012-11-30

Applicant: NOVO NORDISK A/S

Inventor： Vibeke Westphal Stennicke ,  Christine Brender Read ,  Susanne Nedergaard Grell ,  Charlotte Wiberg ,  Rune Salbo ,  Anette Henriksen ,  Soeren Padkjaer

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。

公开(公告)号：US20170298130A1

公开(公告)日：2017-10-19

申请号：US15325865

申请日：2015-07-17

Applicant: NOVO NORDISK A/S

Inventor： Anette Henriksen ,  Kristian Kjærgaard ,  Vibeke Westphal Stennicke ,  Charlotte Wiberg

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US08981061B2

公开(公告)日：2015-03-17

申请号：US13690828

申请日：2012-11-30

Applicant: Novo Nordisk A/S

Inventor： Marco Colonna ,  Axel Bouchon ,  Rune Salbo ,  Charlotte Wiberg ,  Vibeke W. Stennicke ,  Anette Henriksen ,  Mette D. Andersen

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  C07K14/705

CPC classification number: C07K16/2803 ,  C07K14/70503 ,  C07K16/28 ,  C07K2317/76

Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

Abstract translation: 提供了称为TREM（在骨髓细胞上表达的触发受体）的人类骨髓细胞上表达的lg超家族的新型活化受体。 具体地说，公开了TREMs，TREM-1和TREM-2的两（2）个成员。 TREM-1是一种在血液嗜中性粒细胞和单核细胞亚群上有选择性表达而不是淋巴细胞和其他细胞类型的跨膜糖蛋白，并被细菌和真菌产品上调。 还提供了TREM-1在各种炎性疾病的治疗和诊断中的应用。 TREM-2也是在肥大细胞和外周树突状细胞（DC）上选择性表达但不在粒细胞或单核细胞上表达的跨膜糖蛋白。 通过TREM-2的DC刺激导致DC成熟和对凋亡的抗性，并且诱导CCR7的强烈上调和随后对巨噬细胞炎症蛋白3-＆bgr的趋化性。 TREM-2可用于调节各种免疫疾病中的宿主免疫应答，包括自身免疫性疾病和过敏性疾病。

公开(公告)号：US20130309239A1

公开(公告)日：2013-11-21

申请号：US13954318

申请日：2013-07-30

Applicant: Novo Nordisk A/S

Inventor： Vibeke Westphal Stennicke ,  Christine Brender Read ,  Susanne Nedergaard Grell ,  Charlotte Wiberg ,  Rune Salbo ,  Anette Henriksen ,  Soeren Padkjaer

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US10189904B2

公开(公告)日：2019-01-29

申请号：US15372600

申请日：2016-12-08

Applicant: Novo Nordisk A/S

Inventor： Vibeke Westphal Stennicke ,  Christine Brender Read ,  Susanne Nedergaard Grell ,  Charlotte Wiberg ,  Rune Salbo ,  Anette Henriksen ,  Soeren Padkjaer

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US20180105590A9

公开(公告)日：2018-04-19

申请号：US15372600

申请日：2016-12-08

Applicant: Novo Nordisk A/S

Inventor： Vibeke Westphal STENNICKE ,  Christine Brender Read ,  Susanne Nedergaard Grell ,  Charlotte Wiberg ,  Rune SaIbo ,  Anette Henriksen ,  Soeren Padkjaer

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US09000127B2

公开(公告)日：2015-04-07

申请号：US13690748

申请日：2012-11-30

Applicant: Novo Nordisk A/S

Inventor： Vibeke Westphal Stennicke ,  Christine Brender Read ,  Susanne Nedergaard Grell ,  Charlotte Wiberg ,  Rune Salbo ,  Anette Henriksen ,  Soeren Padkjaer

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Abstract translation: 本发明涉及能够特异性结合TREM-1并防止TREM-1的活化的抗体，TREM-1是在单核细胞，巨噬细胞和嗜中性粒细胞上表达的蛋白质。 这种抗体可用于治疗具有炎性疾病的个体，例如类风湿性关节炎和炎症性肠病。

公开(公告)号：US10179814B2

公开(公告)日：2019-01-15

申请号：US15325865

申请日：2015-07-17

Applicant: NOVO NORDISK A/S

Inventor： Anette Henriksen ,  Kristian Kjærgaard ,  Vibeke Westphal Stennicke ,  Charlotte Wiberg

IPC: C07K16/28

Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US20160251434A1

公开(公告)日：2016-09-01

申请号：US14616470

申请日：2015-02-06

Applicant: Novo Nordisk A/S

Inventor： Marco Colonna ,  Axel Bouchon ,  Rune Salbo ,  Charlotte Wiberg ,  Vibeke Westphal Stennicke ,  Anette Henriksen ,  Mette Dahl Andersen

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K14/70503 ,  C07K16/28 ,  C07K2317/76

Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

Abstract translation: 提供了称为TREM（在骨髓细胞上表达的触发受体）的人类骨髓细胞上表达的lg超家族的新型活化受体。 具体地说，公开了TREMs，TREM-1和TREM-2的两（2）个成员。 TREM-1是一种在血液嗜中性粒细胞和单核细胞亚群上有选择性表达而不是淋巴细胞和其他细胞类型的跨膜糖蛋白，并被细菌和真菌产品上调。 还提供了TREM-1在各种炎性疾病的治疗和诊断中的应用。 TREM-2也是在肥大细胞和外周树突状细胞（DC）上选择性表达但不在粒细胞或单核细胞上表达的跨膜糖蛋白。 通过TREM-2的DC刺激导致DC成熟和抗凋亡，并且诱导CCR7的强烈上调和随后对巨噬细胞炎症蛋白3-β的趋化性。 TREM-2可用于调节各种免疫疾病中的宿主免疫应答，包括自身免疫性疾病和过敏性疾病。